US Capitol Capsule: Biopharma patent law back at Supreme Court with Copaxone
This article was originally published in Scrip
Executive Summary
The US Supreme Court is starting off its 2014-15 session with yet another patent case involving biopharmaceutical companies – this time Teva and its money-maker multiple sclerosis drug Copaxone (glatiramer acetate), whose last remaining patent was declared invalid by the US Court of Appeals for the Federal Circuit in July 2013.